What is ArriVent BioPharma, Inc.'s net investment in lease?

ArriVent BioPharma, Inc. (AVBP) reported net investment in lease of $370K in Q1 2026.

How has ArriVent BioPharma, Inc.'s net investment in lease changed year-over-year?

ArriVent BioPharma, Inc.'s net investment in lease increased by 208.3% year-over-year, from $120K to $370K.

What is the long-term trend for ArriVent BioPharma, Inc.'s net investment in lease?

Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s net investment in lease has grown at a -78.9% compound annual growth rate (CAGR), from $291K to $13K.

ArriVent BioPharma, Inc. AVBP Net Investment in Lease

Net Investment in Lease at other companies

Syndax PharmaceuticalsSNDX

——

Nuvation BioNUVB

——

ImmunomeIMNM

——

Erasca, Inc.ERAS

——

Bicara TherapeuticsBCAX

——

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Operating income-$46.1M+30.9%

Net income-$43.3M+32.7%

EPS (diluted)-$0.96+49.5%

Balance sheet

See full

Cash & equivalents$62.1M+24.5%

Total debt$419.0K+204%

Total equity$324.0M+60.0%

Total assets$349.3M+62.1%

Cash flow

See full

Operating cash flow-$41.9M+38.4%

Valuation

See full

Market cap$1.57B+62.1%

Enterprise value$1.51B+65.4%

Returns & leverage

See full

Return on equity-55.2%+8.0pp

Debt / equity0×0.0×

Current ratio14×-0.4×

Where this comes from

Reported directly by ArriVent BioPharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about ArriVent BioPharma, Inc.'s net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ArriVent BioPharma, Inc.'s net investment in lease?: ArriVent BioPharma, Inc. (AVBP) reported net investment in lease of $370K in Q1 2026.
How has ArriVent BioPharma, Inc.'s net investment in lease changed year-over-year?: ArriVent BioPharma, Inc.'s net investment in lease increased by 208.3% year-over-year, from $120K to $370K.
What is the long-term trend for ArriVent BioPharma, Inc.'s net investment in lease?: Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s net investment in lease has grown at a -78.9% compound annual growth rate (CAGR), from $291K to $13K.